Searle Celebrex Rxs Climb 5%; Merck Dental Work Bolsters Vioxx New Rxs
Executive Summary
Celebrex refills are helping Searle weather a 10% downturn in new scripts in the third quarter and to maintain the COX-2 inhibitor's position in the valuable chronic use market, Searle CEO Alan Heller said during an Oct. 27 presentation to the CIBC World Markets Health Care Conference in New York City.